Harpoon Therapeutics to Participate in the Canaccord Horizons in Oncology Conference
April 10 2023 - 4:05PM
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage
immuno-oncology company developing novel T cell engagers, today
announced that Julie Eastland, President and Chief Executive
Officer, and Luke Walker, M.D., Chief Medical Officer, will
participate in a panel and one-on-one meetings with institutional
investors at the virtual Canaccord Horizons in Oncology Conference
on April 20, 2023. The panel titled “T-Cell Engagers Coming of Age”
will take place from 11:00-11:45 a.m. ET.
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immuno-oncology company
developing a novel class of T cell engagers that harness the power
of the body’s immune system to treat patients suffering from cancer
and other diseases. T cell engagers are engineered proteins that
direct a patient’s own T cells to kill target cells that express
specific proteins, or antigens, carried by the target cells. Using
its proprietary Tri-specific T cell Activating Construct (TriTAC®)
platform, Harpoon is developing a pipeline of novel TriTACs
initially focused on the treatment of solid tumors and hematologic
malignancies. Harpoon has also developed a proprietary ProTriTAC™
platform, which applies a prodrug concept to its TriTAC platform to
create a therapeutic T cell engager that remains inactive until it
reaches the tumor. Harpoon’s third proprietary technology platform,
extended release TriTAC-XR, is designed to mitigate cytokine
release syndrome. For additional information about Harpoon
Therapeutics, please visit www.harpoontx.com.
Contacts:
ICR Westwicke:Robert H. UhlManaging
Director858-356-5932robert.uhl@westwicke.com
Media:uncapped
Communications303-588-0599kerry.walton@uncappedcommunications.com
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From Sep 2023 to Sep 2024